MX2021007070A - Mutantes de proteina f de rsv. - Google Patents

Mutantes de proteina f de rsv.

Info

Publication number
MX2021007070A
MX2021007070A MX2021007070A MX2021007070A MX2021007070A MX 2021007070 A MX2021007070 A MX 2021007070A MX 2021007070 A MX2021007070 A MX 2021007070A MX 2021007070 A MX2021007070 A MX 2021007070A MX 2021007070 A MX2021007070 A MX 2021007070A
Authority
MX
Mexico
Prior art keywords
rsv
protein mutants
protein
mutants
compositions
Prior art date
Application number
MX2021007070A
Other languages
English (en)
Inventor
Ping Cai
Xiayang Qiu
Philip Ralph Dormitzer
Mark Edward Ruppen
Avvari Krishna Prasad
Ye Che
Alexey Vyacheslavovich Gribenko
Luke David Handke
Xi Song
Kena Anne Swanson
Srinivas Kodali
KariAnn Sweeney Efferen
Kristin Rachael Tompkins
Lorna del Pilar Nunez
Xin Xu
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2021007070A publication Critical patent/MX2021007070A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/155Paramyxoviridae, e.g. parainfluenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/20Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/20Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/20Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/22Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/40Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18511Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18511Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18511Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18571Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente descripción se relaciona con mutantes, ácidos nucleicos o vectores de proteína F de RSV, que codifican un mutante de proteína F de RSV, composiciones o ácidos nucleicos que comprenden un mutante de proteína F de RSV, y usos de los mutantes, ácidos nucleicos o vectores de proteína F de RSV y composiciones.
MX2021007070A 2015-12-23 2018-06-20 Mutantes de proteina f de rsv. MX2021007070A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562387270P 2015-12-23 2015-12-23
US201662421184P 2016-11-11 2016-11-11

Publications (1)

Publication Number Publication Date
MX2021007070A true MX2021007070A (es) 2021-08-11

Family

ID=57590746

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018007622A MX2018007622A (es) 2015-12-23 2016-12-09 Mutantes de proteina f de rsv.
MX2021007070A MX2021007070A (es) 2015-12-23 2018-06-20 Mutantes de proteina f de rsv.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018007622A MX2018007622A (es) 2015-12-23 2016-12-09 Mutantes de proteina f de rsv.

Country Status (18)

Country Link
US (5) US9950058B2 (es)
EP (1) EP3393512A1 (es)
JP (4) JP6817307B2 (es)
KR (3) KR102505354B1 (es)
CN (1) CN108738312A (es)
AU (4) AU2016379097C1 (es)
BR (1) BR112018010805A2 (es)
CA (2) CA2952131C (es)
CO (1) CO2018006301A2 (es)
IL (2) IL311990A (es)
MX (2) MX2018007622A (es)
PE (3) PE20240817A1 (es)
PH (1) PH12018501355A1 (es)
RU (1) RU2723039C2 (es)
SA (2) SA518391839B1 (es)
SG (2) SG10202001389PA (es)
TW (4) TWI756828B (es)
WO (1) WO2017109629A1 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6685903B2 (ja) 2013-07-25 2020-04-22 アバター・メディカル・エルエルシー 立体構造的に安定化されたrsv融合前fタンパク質
US9630994B2 (en) 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
MX2019011869A (es) 2017-04-04 2020-01-09 Univ Washington Nanoestructuras proteicas auto-ensamblables que muestran proteinas f de paramixovirus y/o neumovirus y su uso.
EP3664836A4 (en) 2017-08-07 2021-05-19 Calder Biosciences Inc. PRE-FUSION RSV PRE-FUSION STABILIZED IN TERMS OF CONFORMITY
CA3088546A1 (en) * 2018-01-29 2019-08-01 Merck Sharp & Dohme Corp. Stabilized rsv f proteins and uses thereof
AU2019228551A1 (en) 2018-02-28 2020-10-15 University Of Washington Self-assembling nanostructure vaccines
CN112601545A (zh) 2018-08-07 2021-04-02 葛兰素史密丝克莱恩生物有限公司 工艺和疫苗
CA3117275A1 (en) * 2018-11-13 2020-05-22 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
CN110054668B (zh) * 2019-04-25 2021-09-10 北京交通大学 一种呼吸道合胞病毒融合前f蛋白及其应用
EP4004018A1 (en) 2019-07-24 2022-06-01 GlaxoSmithKline Biologicals SA Modified human cytomegalovirus proteins
WO2021046207A1 (en) 2019-09-04 2021-03-11 University Of Washington Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use
KR20220116516A (ko) * 2019-12-23 2022-08-23 미쓰비시 타나베 파마 코퍼레이션 변이형 rsv f 단백질 및 그 이용
TW202413391A (zh) 2020-06-21 2024-04-01 美商輝瑞股份有限公司 人巨細胞病毒糖蛋白B(gB)多肽
CN112899214B (zh) * 2020-07-07 2023-08-04 湖南师范大学 废弃鱼鳞在制备各向异性基底中的应用
JP2022023814A (ja) 2020-07-27 2022-02-08 ファイザー・インク 組換え生産された三量体型のrsvタンパク質の精製方法
JP2022023813A (ja) 2020-07-27 2022-02-08 ファイザー・インク 組換え生産されたrsvタンパク質の精製方法における陰イオン交換クロマトグラフィー用洗浄溶液の改良
CN112226444B (zh) * 2020-08-25 2022-11-04 北京交通大学 呼吸道合胞病毒全长融合前融合糖蛋白核苷酸序列、重组腺病毒载体及其应用产品
JP2022060169A (ja) 2020-10-02 2022-04-14 ファイザー・インク Rsv fタンパク質生産のための細胞培養工程
CN114685676B (zh) * 2020-12-28 2024-02-13 兰州生物制品研究所有限责任公司 一种重组蛋白及其表达方法、纯化方法及用途
EP4294436A1 (en) * 2021-02-19 2023-12-27 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv fb fantigens
WO2022234405A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against bacterial and betacoronavirus infections
WO2023144665A1 (en) 2022-01-28 2023-08-03 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins
WO2023208206A1 (zh) * 2022-04-29 2023-11-02 北京新合睿恩生物医疗科技有限公司 Rsv f蛋白突变体及其应用
WO2024041772A1 (en) * 2022-08-22 2024-02-29 Glaxosmithkline Biologicals Sa Rsv-f proteins
CN116003536A (zh) * 2022-09-23 2023-04-25 暨南大学 呼吸道合胞病毒融合前f蛋白突变体及其应用
WO2024069420A2 (en) 2022-09-29 2024-04-04 Pfizer Inc. Immunogenic compositions comprising an rsv f protein trimer
WO2024078597A1 (en) * 2022-10-13 2024-04-18 Rvac Medicines (Us) , Inc. Rsv f protein variants and uses thereof
WO2024089633A1 (en) 2022-10-27 2024-05-02 Pfizer Inc. Rna molecules encoding rsv-f and vaccines containing them
WO2024089634A1 (en) 2022-10-27 2024-05-02 Pfizer Inc. Immunogenic compositions against influenza and rsv
CN117986382A (zh) * 2022-11-04 2024-05-07 北京康乐卫士生物技术股份有限公司 针对rsv的重组亚单位疫苗及其应用
CN116284266B (zh) * 2022-11-21 2024-01-19 怡道生物科技(苏州)有限公司 突变型呼吸道合胞病毒融合前f蛋白及其应用
US20240252612A1 (en) 2022-12-11 2024-08-01 Pfizer Inc. Immunogenic compositions and uses thereof
WO2024154048A1 (en) 2023-01-18 2024-07-25 Pfizer Inc. Vaccines against respiratory diseases
CN117487823A (zh) * 2023-09-28 2024-02-02 怡道生物科技(苏州)有限公司 呼吸道合胞体病毒mRNA疫苗及其制备方法和应用
CN117304280B (zh) * 2023-11-28 2024-04-16 江苏瑞科生物技术股份有限公司 一种重组rsv f蛋白及其应用
CN117304278B (zh) * 2023-11-28 2024-04-16 江苏瑞科生物技术股份有限公司 一种重组rsv f蛋白及其应用
CN117304279B (zh) * 2023-11-28 2024-04-16 江苏瑞科生物技术股份有限公司 一种重组rsv f蛋白及其应用
CN117586359A (zh) * 2024-01-19 2024-02-23 北京安百胜生物科技有限公司 一种具有免疫原性的呼吸道合胞病毒(rsv)多肽
CN117567652B (zh) * 2024-01-19 2024-05-14 北京安百胜生物科技有限公司 一种重组呼吸道合胞病毒颗粒抗原
CN117645655B (zh) * 2024-01-26 2024-05-24 普大生物科技(泰州)有限公司 一种肺炎球菌多糖-rsv重组蛋白结合疫苗及其制备方法
CN117777251B (zh) * 2024-02-27 2024-06-04 普大生物科技(泰州)有限公司 一种rsv纳米颗粒疫苗及其制备方法
CN118064456A (zh) * 2024-03-01 2024-05-24 嘉译生物医药(杭州)有限公司 一种针对人合胞病毒的新型的RSV B mRNA疫苗

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
US5340740A (en) 1992-05-15 1994-08-23 North Carolina State University Method of producing an avian embryonic stem cell culture and the avian embryonic stem cell culture produced by the process
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
FR2726003B1 (fr) 1994-10-21 2002-10-18 Agronomique Inst Nat Rech Milieu de culture de cellules embryonnaires totipotentes aviaires, procede de culture de ces cellules, et cellules embryonnaires totipotentes aviaires
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
TW200636064A (en) 2004-10-28 2006-10-16 Centocor Inc Anti-respiratory syncytial virus antibodies, antigens and uses thereof
EP2181121A4 (en) 2007-03-21 2012-07-11 Id Biomedical Corp Quebec CHIMÄRE ANTIGENE
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
US20100261155A1 (en) 2007-06-06 2010-10-14 Nationwide Children's Hospital, Inc. Methods and compositions relating to viral fusion proteins
EP3109258B1 (en) * 2007-12-24 2019-01-23 ID Biomedical Corporation of Quebec Recombinant rsv antigens
KR20110045008A (ko) 2008-07-18 2011-05-03 아이디 바이오메디컬 코포레이션 오브 퀘벡 키메라 호흡기 세포융합 바이러스 폴리펩티드 항원
WO2010039224A2 (en) 2008-09-30 2010-04-08 University Of Massachusetts Medical School Respiratory syncytial virus (rsv) sequences for protein expression and vaccines
MX2011006205A (es) 2008-12-09 2011-09-01 Novavax Inc Proteinas f del vrs modificadas y metodos de uso de las mismas.
EP2445527A2 (en) * 2009-06-24 2012-05-02 ID Biomedical Corporation of Quebec Vaccine
PL2445526T3 (pl) * 2009-06-24 2017-08-31 Glaxosmithkline Biologicals S.A. Rekombinowane antygeny rsv
ES2918381T3 (es) 2009-07-15 2022-07-15 Glaxosmithkline Biologicals Sa Composiciones de proteína F de VRS y métodos para producir las mismas
WO2011043643A1 (en) 2009-10-06 2011-04-14 Medimmune Ltd Rsv-specific binding molecule
WO2012021730A2 (en) * 2010-08-11 2012-02-16 Genvec, Inc. Respiratory syncytial virus (rsv) vaccine
LT2667892T (lt) 2011-01-26 2019-05-10 Glaxosmithkline Biologicals Sa Rsv imunizacijos režimas
SI2707385T1 (en) * 2011-05-13 2018-01-31 Glaxosmithkline Biologicals Sa Pregnant RSV F antigens
ES2395677B1 (es) 2011-07-29 2013-12-26 Instituto De Salud Carlos Iii Proteína F del VRSH en conformación pre-fusión estabilizada y anticuerpos neutralizantes específicos frente a la misma.
CN104080476A (zh) 2011-09-30 2014-10-01 诺瓦瓦克斯股份有限公司 用于呼吸道合胞病毒的重组纳米颗粒rsv f疫苗
JP5845376B2 (ja) 2012-03-22 2016-01-20 クルセル ホランド ベー ヴェー Rsvに対するワクチン
EP2922570A1 (en) 2012-11-20 2015-09-30 GlaxoSmithKline Biologicals SA Rsv f prefusion trimers
FI2970398T3 (fi) * 2013-03-13 2024-08-06 Us Health Rsv f -prefuusioproteiineja ja niiden käyttö
US9738689B2 (en) * 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
ME03442B (me) 2013-04-25 2020-01-20 Janssen Vaccines & Prevention Bv Stabilizovani rastvorljivi pre-fuzioni rsv f polipeptidi
CN105408348B (zh) 2013-06-17 2021-07-06 扬森疫苗与预防公司 稳定化的可溶性融合前rsv f多肽
JP6685903B2 (ja) 2013-07-25 2020-04-22 アバター・メディカル・エルエルシー 立体構造的に安定化されたrsv融合前fタンパク質
US20150166610A1 (en) * 2013-10-14 2015-06-18 Glaxosmithkline Biologicals, S.A. Recombinant rsv antigens
EP2974739A1 (en) * 2014-07-15 2016-01-20 Novartis AG RSVF trimerization domains
CA2996762A1 (en) * 2015-08-31 2017-03-09 Technovax, Inc. Human respiratory syncytial virus (hrsv) virus-like particles (vlps) based vaccine
US10496141B2 (en) 2016-03-17 2019-12-03 Qualcomm Incorporated System and method for intelligent thermal management in a system on a chip having a heterogeneous cluster architecture

Also Published As

Publication number Publication date
AU2019210579A1 (en) 2019-08-22
US20170182151A1 (en) 2017-06-29
IL260203A (en) 2018-07-31
TW201920238A (zh) 2019-06-01
JP2022185022A (ja) 2022-12-13
KR20200090932A (ko) 2020-07-29
JP2021061845A (ja) 2021-04-22
CA3217696A1 (en) 2017-06-23
PE20181354A1 (es) 2018-08-22
WO2017109629A1 (en) 2017-06-29
RU2020115606A3 (es) 2020-11-23
JP7212198B2 (ja) 2023-01-24
EP3393512A1 (en) 2018-10-31
AU2023214269A1 (en) 2023-10-12
RU2018122823A3 (es) 2020-01-23
SG10202001389PA (en) 2020-04-29
TW202216738A (zh) 2022-05-01
US9950058B2 (en) 2018-04-24
CN108738312A (zh) 2018-11-02
US10238732B2 (en) 2019-03-26
RU2020115606A (ru) 2020-06-29
PE20240817A1 (es) 2024-04-18
AU2016379097B2 (en) 2019-08-22
JP6817307B2 (ja) 2021-01-20
KR102505354B1 (ko) 2023-03-02
SA522433260B1 (ar) 2024-06-24
US10821171B2 (en) 2020-11-03
US20210023200A1 (en) 2021-01-28
SG11201804148TA (en) 2018-07-30
PH12018501355A1 (en) 2019-02-18
CA2952131C (en) 2023-12-05
SA518391839B1 (ar) 2023-10-22
KR20230035429A (ko) 2023-03-13
BR112018010805A2 (pt) 2018-11-27
KR20180081614A (ko) 2018-07-16
US20180177864A1 (en) 2018-06-28
TW202124414A (zh) 2021-07-01
AU2016379097A1 (en) 2018-06-07
US20230218738A1 (en) 2023-07-13
AU2019210579B2 (en) 2021-01-28
MX2018007622A (es) 2018-11-14
TWI656130B (zh) 2019-04-11
KR102136678B1 (ko) 2020-07-22
AU2016379097C1 (en) 2021-04-08
TWI707866B (zh) 2020-10-21
IL311990A (en) 2024-06-01
CA2952131A1 (en) 2017-06-23
AU2021202522C1 (en) 2023-11-23
JP2019511998A (ja) 2019-05-09
RU2723039C2 (ru) 2020-06-08
JP2023015335A (ja) 2023-01-31
AU2021202522A1 (en) 2021-05-27
RU2018122823A (ru) 2020-01-23
AU2021202522B2 (en) 2023-05-11
CO2018006301A2 (es) 2018-07-10
TWI756828B (zh) 2022-03-01
JP7193522B2 (ja) 2022-12-20
IL260203B1 (en) 2024-05-01
TWI838685B (zh) 2024-04-11
TW201726709A (zh) 2017-08-01
PE20232039A1 (es) 2023-12-21
US20190125861A1 (en) 2019-05-02

Similar Documents

Publication Publication Date Title
PH12018501355A1 (en) Rsv f protein mutants
EP3741848A3 (en) Protease variants and polynucleotides encoding same
PH12019500540A1 (en) Anti-pd-1 antibodies and their uses
WO2016066756A3 (en) Protease variants and polynucleotides encoding same
WO2016066757A3 (en) Protease variants and polynucleotides encoding same
MX2023010757A (es) Variantes de proteasa y sus usos.
EP3741849A3 (en) Protease variants and polynucleotides encoding same
PH12019501357A1 (en) Anti-ox40 antibodies and their uses
EP3708660A3 (en) Polypeptides
PH12018502456A1 (en) Anti-cd04 antibodies and their uses
MX2017007731A (es) Composiciones de detergente, variantes de lipasa y polinucleotidos que codifican las mismas.
TN2018000276A1 (en) Inhibitors of receptor-interacting protein kinase 1.
MX2017014125A (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
MX2019000140A (es) Variantes de xilanasa y polinucleotidos que las codifican.
WO2015048333A3 (en) Nutritive polypeptides and formulations thereof, and methods of production and use thereof
WO2015014790A3 (en) Protease variants and polynucleotides encoding same
WO2016062875A3 (en) Glucoamylase variants and polynucleotides encoding same
MX2018008051A (es) Variantes de beta-glucanasa y polinucleotidos que las codifican.
MX2022001085A (es) Anticuerpos anti-c1s humanizados y metodos para usarlos.
EP3964575A3 (en) Alpha-amylase variants and polynucleotides encoding same
WO2016140859A3 (en) Protoxin-ii variants and methods of use
WO2017112847A8 (en) Improved protein expression strains
MX2023003394A (es) Variantes de proteasa y sus usos.
MX2017007105A (es) Variantes de lipasa y polinucleotidos que las codifican.
MX2017008908A (es) Proceso para la hidrólisis de queratina empleando proteasas.